Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T13:46:00.124Z.
Calculation as of: 2026-10-06T13:46:00.124Z.
Quote observation: 2026-10-06T13:44:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d42caa3e816b0495fa2340ecfe28e9cd39b3fd8bb52e96b9f838481ccca068c7
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | $329.60M | N/A | N/A | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $336.71M | N/A | N/A | N/A | N/A |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $341.86M | N/A | N/A | N/A | N/A |
| CapsoVision, Inc. (CV)vs › | $323.01M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $310.39M | N/A | 396.83 | 396.83 | 396.83 |
| ClearPoint Neuro, Inc. (CLPT)vs › | $344.13M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $345.29M | 3.93 | 4.83 | 10.37 | 9.91 |
| Agenus Inc. (AGEN)vs › | $352.29M | 3.20 | 2.74 | 2.74 | 27.61 |
| Standard BioTools Inc. (LAB)vs › | $305.38M | N/A | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $359.16M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.98
Forward EPS (Est.)
$-0.87
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
